OKT3 monoclonal antibody reversal of acute renal allograft rejection unresponsive to conventional immunosuppressive treatments.
Year: 1986
Type: article
Abstract: ORTHOCLONE OKT3 was shown, in a randomized multicenter trial for acute rejection of cadaveric renal transplants, to reverse 94 percent of the rej ecti ons as contrasted with a 75 percent reversal rate obtained with conventional steroid treatment (P=O.009).Thi s superi or reversal rate wi th OKT3 was refl ected in an improved one-year graft survival rate (62 percent) as compared with the steroid-treated group (45 percent).We now present the results of a clinical trial involving 173 patients with acute renal allograft rejection that failed to respond to conventional immunosuppressive therapies.OKT3 rilonoclonal anti body was gi ven for a 10-14 day course and the dosage of other immunosuppressive drugs was reduced.Acute rejection was reversed by OKT3 monoclonal antibody in 121 patients (70 percent) and actuarial graft survival at 6 months was 52 percent.The therapeutic properties of OKT3 are ascribed to blocking of the T3-antigen-receptor
Source: PubMed
Authors: G Goldstein, D J Norman, C F Shield, H Kreis, J Burdick, M W Flye, E Rivolta, T Starzl, A Monaco
Language: English
Subfield: Transplantation
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W15266632